MedTrace Logo

Orexigenic Therapy With Delta-9-tetrahydrocannabinol in Advanced Cancer Patients With Chemosensory Abnormalities - a Pilot Study

NCT00316563 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2010-02-09

No results posted yet for this study

Summary

To investigate delta-9-tetrahydrocannabinol's (THC) ability to increase food intake and improve food enjoyment for advanced cancer patients with taste and/or smell (chemosensory) abnormalities.

Conditions

  • Cancer
  • Anorexia
  • Taste Disorders
  • Olfactory Disorders

Interventions

DRUG

Marinol (Dronabinol)

Intervention description: Marinol (drug) is being used as an appetite stimulant for treatment of cancer-induced anorexia.

OTHER

Placebo

Sponsors & Collaborators

  • University of Alberta

    collaborator OTHER

  • Alberta Health services

    lead OTHER

Principal Investigators

  • Ingrid H. de Kock, MD · AHS Cancer Control Alberta

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Completion
2009-11-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00316563 on ClinicalTrials.gov